Introduction: The 1996 ‘Declaration of Nutrition Health and Intelligence for the Child to Be’ called for optimal nutrition through pregnancy. Vitamin B12 is a water-soluble vitamin available in foods of animal origin. Estimates of deficiency prior to conception, in pregnancy and infancy in low and low-middle-income countries have been reported. Vitamin B12 is a critical element in a wide ecology of cofactors that support single carbon metabolism and energy production. Biologically its role in brain growth and development includes the production of myelin, neurotransmitters and cell dynamics through DNA synthesis. Vitamin B12 deficiency in pregnancy has been associated with delayed infant neurodevelopment.
Methods: The MATCOBIND trial measured the effects of two doses of B12 supplement given to pregnant women, predominantly vegetarian, in New Delhi, India (n=370) and Kathmandu, Nepal (n=338). Participating mothers were randomized to receive oral methyl-cobalamin of 250μg (Group A) or 50μg (Group B) daily from enrollment until 6-months postpartum. Infant development was measured at 9-12 months of age as well as blood levels of B12 in mothers and their infants. Trial Registration: Clinical Trial Registry of India (CTRI/2018/07/015048) and at ClinicalTrials.gov (ID NCT04083560). Volunteer mothers were recruited from diverse populations of mothers from varied socioeconomic backgrounds. Most were taking a vegetarian diet and received routine iron and folic acid supplementation during their pregnancy. The majority of their infants were exclusively breast fed. Compliance with B12 supplementation was good.
Results: 531 mothers completed the study. Mental Developmental quotients were higher in the infants of Group-A mothers (103.7) than Group-B (101.7; p=0.008). This corresponded to a mean difference of 7.8 centiles (p=0.007). Motor Developmental Quotients were not significantly different between the groups. Maternal vitamin B12 levels increased between the 1st and 3rd trimesters in both groups: the Group-A mean was 104.9 pg/ml [SD 159.1]; Group-B mean was 47.5 pg/ml [SD 118.0]; (p<0.001). All Infant levels of vitamin B12 were within the normal range.
Newborn anthropometry, APGAR Scores and morbidity profiles were similar in both groups (p>0.05). Infant milk feeding, complementary feeding, interval morbidity, growth and HOME environment scores were comparable too (p>0.05). Serum Ferritin, vitamin-D and folate were similar (p>0.05).
Conclusions: Low availability of vitamin B12 in vegetarian diets challenges the B12 status of many mothers in low and middle income countries, particularly during pregnancy. Infant mental DQ and maternal B12 status at 9-12 months were significantly improved by daily supplementation with 250 μg of vitamin B12 during pregnancy in this study, when compared with a lower dose supplement of 50 μg. It is not known whether developmental impacts of maternal vitamin B12 supplements were sustained when our subjects became older. Although Gowland Hopkins stated in 1932 that vitamins will not make 'super babies', their roles have not been fully explored. Public health considerations can build this evidence into considerations of how best to manage vegetarianism, as can mothers on vegan or vegetarian diets planning their pregnancies.

